SCHEMBL30348718

SCHEMBL30348718

CC(=O)N1C[C@H]2CC(Nc3ncc4c(-c5ccc6nnccc6c5)c[nH]c4n3)C[C@H]2C1

nearest known ligand 0.40

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ DYRK1A Q13627 2/20 0.40
▸ CLK2 P49760 1/20 0.40
▸ CLK3 P49761 1/20 0.40
▸ MAP3K11 Q16584 5/20 0.37
▸ JAK1 P23458 4/20 0.37
▸ JAK2 O60674 1/20 0.37
▸ AURKA O14965 1/20 0.33
▸ JUN P05412 4/20 0.33
▸ MAPK8 P45983 4/20 0.33
▸ MAPK9 P45984 4/20 0.33
▸ MAPK10 P53779 2/20 0.33
▸ DYRK1B Q9Y463 1/20 0.32
▸ BRD4 O60885 1/20 0.32
▸ CDK2 P24941 3/20 0.32
▸ CCNT1 O60563 1/20 0.32
▸ CDK9 P50750 1/20 0.32
▸ MAPK1 P28482 1/20 0.31
▸ SGK1 O00141 1/20 0.31
▸ MAP4K1 Q92918 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25522537 1.00 DYRK1A (0.40) DYRK1ACLK2CLK3MAP3K11JAK1
SCHEMBL25522534 1.00 DYRK1A (0.40) DYRK1ACLK2CLK3MAP3K11JAK1
SCHEMBL31568822 0.88 DYRK1A (0.42) DYRK1ACLK2CLK3MAP3K11JAK1
SCHEMBL25522526 0.88 DYRK1A (0.42) DYRK1ACLK2CLK3MAP3K11JAK1
SCHEMBL25522657 0.88 DYRK1A (0.40) DYRK1ACLK2CLK3MAP3K11JAK1
SCHEMBL30346692 0.88 DYRK1A (0.40) DYRK1ACLK2CLK3MAP3K11JAK1
SCHEMBL25522658 0.88 DYRK1A (0.40) DYRK1ACLK2CLK3MAP3K11JAK1
SCHEMBL30348361 0.85 DYRK1A (0.38) DYRK1ACLK2CLK3MAP3K11JUN
SCHEMBL30347709 0.85 CLK2 (0.40) DYRK1ACLK2CLK3MAP3K11JUN
SCHEMBL25522539 0.85 DYRK1A (0.38) DYRK1ACLK2CLK3MAP3K11JUN

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250129104-A1 7H-PYRROLO[2,3-D]PYRIMIDINES AND PREPARATION AND USES THEREOF TENARX, INC. 2025-04-24 — — US claimed
EP-4415818-A1 7H-PYRROLO[2,3-D]PYRIMIDINES AND PREPARATION AS DYRK1A INHIBITORS BioSplice Therapeutics, Inc. (US) 2024-08-21 — — EP claimed
WO-2023064361-A1 7H-PYRROLO[2,3-D]PYRIMIDINES AND PREPARATION AS DYRK1A INHIBITORS BIOSPLICE THERAPEUTICS, INC. (US) 2023-04-20 — — WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250129104-A1 7H-PYRROLO[2,3-D]PYRIMIDINES AND PREPARATION AND USES THEREOF DYRK1A, DYRK1B, DYRK2 DYRK1A 1/4885CLK2 466/4885CLK3 1147/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback